Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues.
Miriam LongoLorenzo ScappaticcioPaolo CirilloAntonietta MaioRaffaela CarotenutoMaria Ida MaiorinoGiuseppe BellastellaKatherine EspositoPublished in: Biomolecules (2022)
Cardiovascular diseases are the leading cause of death in people with diabetes. Diabetic cardiomyopathy (DC) is an important complication of diabetes and represents a distinct subtype of heart failure that occurs in absence of cardiovascular diseases. Chronic hyperglycemia and hyperinsulinemia along with insulin resistance and inflammatory milieu are the main mechanisms involved in the pathophysiology of DC. Changes in lifestyle favoring healthy dietary patterns and physical activity, combined with more innovative anti-diabetes therapies, are the current treatment strategies to safeguard the cardiovascular system. This review aims at providing an updated comprehensive overview of clinical, pathogenetic, and molecular aspects of DC, with a focus on the effects of anti-hyperglycemic drugs on the prevention of pump dysfunction and consequently on cardiovascular health in type 2 diabetes.
Keyphrases
- type diabetes
- glycemic control
- cardiovascular disease
- heart failure
- insulin resistance
- physical activity
- blood glucose
- dendritic cells
- weight loss
- oxidative stress
- metabolic syndrome
- atrial fibrillation
- body mass index
- left ventricular
- adipose tissue
- cardiovascular events
- high fat diet
- sleep quality
- drug induced
- acute heart failure
- single molecule
- cardiac resynchronization therapy
- wound healing